Bacterial LPS induces endothelial cell (EC) injury both in vivo and in vitro. We studied the effect of Escherichia coli 011 1:B4 LPS on movement of '4C-BSA across bovine pulmonary artery EC monolayers. In the presence of serum, a 6-h LPS exposure augmented (P < 0.001) transendothelial 14C-BSA flux compared with the media control at concentrations 2 0.5 ng/ml, and LPS (10 ng/ml) exposures of 2 2-h increased (P < 0.005) the flux. In the absence of serum, LPS concentrations of up to 10 Ag/ml failed to increase 14C-BSA flux at 6 h. The addition of 10% serum increased EC sensitivity to the LPS stimulus by > 10,000-fold. LPS (10 ng/ml, 6 h) failed to increase 14C-BSA flux at serum concentrations < 0.5%, and maximum LPS-induced increments could be generated in the presence of . 2.5%. LPS-binding protein (LBP) and soluble CD14 (sCD14) could each satisfy this serum requirement; either anti-LBP or anti-CD14 antibody each totally blocked (P < 0.00005) the LPS-induced changes in endothelial barrier function. LPS-LBP had a more rapid onset than did LPS-sCD14. The LPS effect in the presence of both LBP and sCD14 exceeded the effect in the presence of either protein alone. These data suggest that LBP and sCD14 each independently functions as an accessory molecule for LPS presentation to the non-CD14-bearing endothelial surface. However, in the presence of serum both molecules are required. (J. Clin. Invest. 1994. 93:692-702.)
Introduction
Gram-negative bacteremia and its attendant endotoxemia can serve as clinical antecedents for adult respiratory distress syndrome (1) . Bacterial LPS induces acute pulmonary vascular endothelial cell (EC) I injury in experimental animals (2) . Mul-tiple host responses have been postulated as mechanisms for LPS-induced lung injury, including: systemic and pulmonary hemodynamic alterations, complement cleavage products, arachidonate metabolites, platelet-activating factor, granulocytes, toxic oxygen intermediates, and proteinases (2) , as well as cytokines (3) . LPS has been shown to augment the movement of '251I-albumin across bovine pulmonary arterial EC monolayers in the absence of hydrostatic pressure changes, granulocyte effector cells, alveolar macrophages, or numerous nonendothelial-derived host mediators (4) . Some LPS-induced EC responses are serum dependent (4, 5) . Recently, an LPS-binding protein (LBP) has been demonstrated in the sera of various species (6) (7) (8) (9) . LBP binds to the lipid A component of LPS (10) , and this LPS-LBP complex recognizes CD14 on host cells of monocyte/macrophage lineage (11) . The endothelium is reportedly a non-CD14-bearing surface (12, 13) . Monocytederived CD 14, which is attached to the plasma membrane via a phosphatidylinositol glycan anchor (14, 15) , can also be present in soluble form in normal serum (14, 16) . This soluble CD14 (sCD 14) may participate in LPS presentation to the EC (17, 18) . In this report, an endotoxin-sensitive pulmonary vascular EC line (4, 5) was used to focus on the direct effect ofLPS on endothelial barrier function and the influence ofserum constituent(s) on this LPS-EC interaction. More specifically, we present evidence that the acute phase protein, LBP, and the monocyte differentiation antigen, CD 14 , can each function as accessory molecules for LPS-induced changes in endothelial barrier function. That monocytic cells shed or release a molecule into the intravascular compartment which in concert with an hepatocyte-synthesized protein can regulate LPS presentation to the non-CD 14-bearing EC surface is novel. trols for sCD 14. CD 14-depleted human serum (HS) was prepared using affinity chromatography. Briefly, anti-human CD 14 mAb 28C5 (1 mg) was immobilized using a ReactigelR matrix (Pierce Chemical Co., Rockford, IL) and was equilibrated with PBS. Pooled-type AB HS (Sigma Chemical Co.) ( 10 ml) was passed through the column. sCD14 bound to the immobilized mAb was eluted using glycin-HCI, pH 2.5.
After reequilibration with PBS, the first flow through was again passed through the column, and the second flow through was considered as CD14-depleted HS. sCD14 concentrations in the starting material were 2 tg/ml HS and < 1 ng/ml in the CD14-depleted serum.
Endothelial cell culture. Bovine pulmonary artery EC (American Type Culture Collection, Rockville, MD) were grown at 370C under 5% CO2 in DME (Sigma Chemical Co.) and were enriched with 20% FBS (Hyclone Laboratories Inc., Logan, UT), 4 mM L-glutamine, nonessential amino acids, and vitamins in the presence of penicillin (50 U/ml) and streptomycin (50 ,g/ml) (Sigma Chemical Co.). EC were washed and were gently detached with a brief ( 1-2 min) trypsin (0.5 mg/ml) (Sigma Chemical Co.) exposure with gentle agitation, followed immediately by neutralization with FBS-containing medium. The cells were counted and were suspended in medium for immediate seeding of assay chambers (4 X 105 cells/ml) or 6-well tissue culture plates (3.0 x I05 cells/ml). Cultures were determined to be endothelial by uniform morphology and quantitative determination of angiotensin-converting enzyme activity with commercially available 'H-benzoyl-Phe-Ala-Pro substrate (Ventrex Laboratories, Portland, ME).
Assay oftransendothelial albumin flux. Transendothelial '4C-BSA flux was assayed as we have described (21 ) . Polycarbonate filters ( 13-mm diameter, 0.4-um pore size) (Nucleopore Corp., Pleasanton, CA) were treated with 0.5% acetic acid (50°C, 20 min), were washed in distilled H20, and were immersed in boiling pig skin gelatin (Fisher Scientific Co., Pittsburgh, PA) (5 mg/liter distilled H20) for 60 min. The filters were then dried, were glued to polystyrene chemotactic chambers (ADAPS Inc., Dedham, MA), and were gas sterilized with ethylene oxide. These chambers, which served as the upper compartment for the assay chambers, were inserted into wells of 24-well plates, each well containing 1.5 ml medium and serving as the lower compartment of the assay chamber. Each upper compartment was seeded with 2 x 105 EC in 0.5 ml medium and was cultured for 72 h (37°C, 5% C02). We used`4C-BSA (Sigma Chemical Co.) with a specific activity of 30.1 PCi/mg protein as the tracer molecule. The baseline barrier function of each monolayer was determined by applying an equivalent and reproducible amount of '4C-BSA ( 1.1 pmol/0.5 ml) to each upper compartment for 1 h at 37°C, after which 0.5 ml from the lower compartment was added to 4.5 ml scintillation fluid (Optifluor; Packard Instruments Co., Inc., Downers Grove, IL) and was counted in a liquid scintillation analyzer (Tri-Carb 1500; Packard Instruments Co., Inc.). Only EC monolayers retaining 2 95% of the '4C-BSA were studied. The monolayers were then exposed to LPS at varying concentrations for increasing exposure times. Simultaneous controls with medium alone were performed. Transfer of '4C-BSA across EC monolayers was again assayed.
In other experiments, serum-dependence for LPS-induced changes in endothelial barrier function was studied. EC were seeded onto gelatin-impregnated filters and were cultured in DME enriched with 20% FBS as above. Over the last 16 h ofthe 72-h incubation, the monolayers were serum-starved in DME alone. At 72 h, baseline barrier function was established using the permeability tracer 14C-BSA in fresh medium containing no FBS but supplemented with BSA (34 g/liter) yielding a final protein concentration equivalent to DME enriched with 10% FBS. The BSA was included to control for potential nonspecific protein-LPS interactions and to minimize nonspecific binding of reagents to plastic. Then, the monolayers were incubated with media containing LPS 10 ng/ml, increasing FBS concentrations, and reciprocally decreasing BSA concentrations so that the same final protein concentration was maintained. Endothelial barrier function again was determined using 14C-BSA with the same fixed BSA concentration used above. Endothelial barrier function also was assayed for serum-starved monolayers after 6-h exposures to increasing LPS concentrations ( I1 -'-10 5 ng/ml) again, in the presence ofthe same fixed BSA concentration used above, in the absence of FBS. To address whether LBP or sCD14 could be operative in the serum-dependent LPS effect, rabbit LBP (6), human LBP (7), or human sCD 14 were each used in selected experiments in lieu of FBS. LBP (mol wt = 60,000) was used at concentrations ( 1.2 ug/ml) equimolar to LPS 100 ng/ml (estimated average mol wt = 5,000) (10) . Human CRP and DAF as well as bovine folate-binding protein were used as protein controls. To establish a dose-response relationship between LBP and LPS-induced barrier dysfunction, increasing concentrations of rabbit LBP together with a fixed LPS concentration ( 100 ng/ml) were studied. Similar studies with varying concentrations of human sCD 14 and the same LPS exposure were also performed. In experiments where LBP was coadministered with sCD14, lower concentrations were used.
In one set of experiments, serum-starved monolayers were studied for barrier function in the presence of 10% HS. The HS was obtained from the same individual, and was immediately aliquoted and frozen. The monolayers were exposed to LPS 100 ng/ml for 6 h with or without preincubation with either murine monoclonal anti-human CD 14 antibody 28C5 (10 Atg/ml) or goat anti-human LBP IgG (1 mg/ml) ( 19) . Simultaneous controls for each antibody preparation alone as well as for species-matched irrelevant antibodies were also performed. In another set ofexperiments, serum-starved monolayers were exposed to LPS 100 ng/ml or media alone for 6 h in the presence of either 10% HS or 10% CD 14-depleted HS from the same donor. These two sera had LBP concentrations of 27 and 23 ,g/ml, respectively.
Effect ofLPS on EC viability. To determine whether LPS-induced changes in endothelial barrier function could be explained by EC injury or loss of viability, LPS-exposed and medium control monolayers were serially studied for lactate dehydrogenase (LDH) release (22) and 5'Cr release (21 ) as we have described previously. EC were seeded into the wells of 24-well plates (2 x 10 5 cells/ well) and were cultured for 72 h to achieve confluence. For the LDH release assay, the medium was decanted and was replaced with medium containing LPS 10 ng/ml or medium alone for increasing exposure times. Supernatants were harvested, and the monolayers were solubilized ( 1% Triton X-100, 0.5 h). LDH activity was assayed in the medium and in the cell lysate (22 (21) . The washed monolayers were incubated with either LPS 10 ng/ml or medium alone for increasing exposure times after which the supernatants were counted. To differentiate between actual EC release of 5'Cr and EC detachment into the supernatants, aliquots of washes were centrifuged (300 g, 10 min) before counting. All washed monolayers were solubilized with 1% Triton X-100 (Sigma Chemical Co.) to induce maximum release. The lysates were centrifuged, and the supernatants were counted for 5'Cr activity. EC injury was expressed as: (5'Cr supernatant)/(5'Cr supernatant plus 5'Cr cell lysate) X 100%.
Statistical methods. The mean response for each experimental group was compared with its respective control by Student's t test. Analyses of variance were used to compare the mean responses among experimental and among control groups. A P value of < 0.05 was considered significant. (10) 5(10) 18 27 (6) 30 38 (8) 18 22 (9) 18 21(10) 20 22 (11) 7(5) E. Coli 0111:B4 LPS Concentration (ng/ml) (n), number of monolayers studied in serum-free conditions. *Significantly increased compared with the simultaneous media control at P < 0.001. **Significantly increased compared with the serum-free media control at P < 0.0001.
pmol/h (n = 288), and the mean (±SE) '4C-BSA transfer across naked filters without EC monolayers was 0.215±0.015 pmol/h. The lowest LPS concentration that induced a significant increment in '4C-BSA flux compared with the media control was 0.5 ng/ml. The maximum mean (±SE) '4C-BSA flux of 0.151±0.016 pmol/h was seen with LPS 1,000 ng/ml, although the LPS-induced effect seemed to plateau or saturate at doses > 10 ng/ml. The LPS effect in the absence of FBS is discussed below.
Time-dependent effect ofLPS on transendothelial '4C-BSA flux. The effect of LPS on endothelial barrier function was also time dependent (Fig. 2) . Transendothelial '4C-BSA flux was assayed immediately after increasing exposure times to LPS 10 ng/ml or media alone. There were no significant differences between`4C-BSA flux across media control monolayers throughout the 6-h study period. LPS 10 ng/ml failed to induce significant increments in '4C-BSA flux compared with simultaneous media controls after 0.5-and 1-h exposures. Only LPS exposures of 2 2 h significantly increased '4C-BSA flux with further time-dependent increments throughout the 6-h study period. These studies demonstrated an LPS stimulus-to-EC response lag time of > 1 h but < 2 h. Effect ofLPS on EC injury or death. Two assays were used to determine whether an LPS exposure (10 ng/ml) that comptomises endothelial barrier function also might induce EC injury or death over the same time period. LPS-exposed and media control monolayers were studied serially for LDH release and 5"Cr release (Table I ). The total cell counts in either group did not change over the study period (data not shown). LDH release was not significantly different between experimental and control groups throughout the study period. In fact, even LPS 100 ng/ml failed to significantly increase LDH release compared with media controls at 6 h (4.05±1.37% vs 2.22±0.81%). When the more sensitive 5"Cr release assay was used, LPS exposure significantly augmented EC 5"Cr release compared with simultaneous media controls at 4 and 6 h. This assay detects defects in the plasma membrane that permit passage of molecules < 1,000 D. Ifone uses LDH release as a more stringent detection system for membrane integrity and cell viability, these data suggest that a < 6-h LPS exposure at 10 ng/ml induces EC membrane perturbation without frank loss of viability.
Influence ofserum on LPS-induced changes in endothelial barrierfunction. The effect of LPS on endothelial barrier function was serum dependent. LPS concentrations < 104 ng/ml failed to increase '4C-BSA flux across serum-starved monolayers in the absence of FBS (Fig. 1, open (Fig. 4) . LPS only in the presence of either FBS or LBP significantly increased transendothelial t4C-BSA flux. The addition of BSA or CRP failed to support the LPS effect. When monolayers were exposed for 6 h to a fixed LPS concentration ( 100 ng/ml) in the presence of varying rabbit LBP concentrations, the LPS/LBP effect increased as the LBP concentration increased (Fig. 5) . LBP concentrations 40 38 (open bars). Mean (±SE) pretreatment baseline is shown by the closed bar.
2 0.1 ,ug/ml in the presence of LPS significantly increased albumin flux compared to LPS alone; LBP alone at 3 ,g/ml had no effect. The maximal LPS/LBP effect was seen in the presence of 1.0 ,ug/ml LBP, a close approximation ofthe estimated equimolar concentration of LBP for LPS at 100 ng/ml (10) . LBP at > 1 ,g/ml was not associated with any further increment in the LPS/LBP effect. These data are compatible with an optimal LPS/ LBP ratio of 1:1 in our experimental system. When HS was used to take advantage of anti-human LBP antibodies, anti-LBP antisera completely blocked the ability of serum to support the LPS-induced endothelial barrier dysfunction (Fig. 6) . In a serum-free reconstituted LPS-human sCD 14 system, anti-LBP antibody had no effect, excluding cross-reactivity of the anti-LBP antibody with sCD 14. Therefore, the single protein LBP could substitute for serum in the promotion of the LPS-induced changes, and in the presence of serum LBP was required.
Role of sCD14 in LPS-induced changes in endothelial barrierfunction. Similarly, the ability ofsCD 14 to alter LPS-induced changes in endothelial barrier function in the absence of serum or LBP was studied (Fig. 7) . LPS with sCD 14 in the suprathreshold concentrations of LPB could not (Fig. 9) . LBP Kinetic analysis of LPS-induced changes in endothelial significantly enhanced the LPS-sCD 14-induced increments barrierfunction in the presence of LBP, sCDJ4, or both. LBP, compared with those seen after exposure to LPS-sCD 14 alone sCD 14, or both accessory molecules together were studied for (Fig. 7) . Therefore, sCD14 functioned as an accessory moletheir ability to promote the LPS-induced changes in barrier cule for LPS in the absence of LBP, and immunoblockade with function over time (Fig. 10 ). All reagents were introduced at anti-CD 14 augments movement of '25I-BSA across similarly passaged bovine pulmonary artery EC cells cultured on filters, also in the presence of 10% FBS. Their LPS concentration was 2 1,000-fold higher than those used in our study. Based on the dose-response relationship between LPS concentration and change in endothelial barrier function, LPS 10 ng/ml in the presence of FBS was used to study the time profile for the LPS-induced effect. A minimum LPS exposure of 2 h was necessary for immediate changes. Using LPS 10 g/ml in a similar experimental system, Meyrick et al. (4) Time (h) Figure 10 . Kinetic analysis of accessory molecule(s) regulation of LPS-induced changes in endothelial barrier function. Transendothelial "4C-BSA flux was determined across serum-starved monolayers immediately after increasing exposure times to serum-free media, LPS 100 ng/ml serum-free media, LPS with LBP (1.2 gg/ml), LPS with sCD14 (50 or 500 ng/ml), and LPS with both LBP and sCD14 (50 ng/ml certain other LPS-induced EC responses, including hyperadhesiveness for neutrophils (23) , and increased expression ofplasminogen activator inhibitor 1 (24), IL-i (25), IL-6 (18, 26), IL-8 (18) , and PDGF (27) . The time requirements for the LPS-induced changes in endothelial barrier function are not unlike those described after either rTNFa (21 ) or rIL-1 (28) exposures. Compared with LPS, most other established mediators of increased endothelial permeability, including histamine, bradykinin, and leukotriene B4, all display a much more rapid onset of action (29) .
To determine whether endothelial barrier dysfunction produced by a c 6-h LPS exposure at 10 ng/ml was mediated through EC injury, two cytotoxicity assays were used. LPS ( 10 ng/ml) failed to increase endothelial cell LDH release over 6 h. LPS failed to increase 51Cr release after 1 or 2 h, but after 4 and 6 h, 51Cr release was minimally but significantly increased. LPS-induced EC cytotoxicity has been well described and is highly dependent on LPS concentration and exposure time, the presence of serum, as well as the species and possibly anatomical origin of the target EC (5, (30) (31) (32) . Most of these earlier studies used higher LPS concentrations and longer LPS exposure times (4, 5, 30, 31, 33, 34) . In our system, LPS induced changes in endothelial barrier function at doses and exposure times ( 10 ng/ml X 2 h), which could not be ascribed to cytotoxicity or loss of viability as measured by these assay systems. On the basis of trypan blue exclusion (data not shown) and increased 5"Cr release, LPS induced sublethal cell injury by 4 and 6 h.
The LPS-induced changes in endothelial barrier function were profoundly serum dependent. LPS (10 ng/ml, 6 h) failed to increase 14C-BSA flux at serum concentrations < 0.5%, and maximum LPS-induced increments could be generated in the presence of . 2.5% FBS. The addition of 10% FBS increased EC sensitivity to the LPS stimulus by > 10,000-fold. LPS-induced EC cytotoxicity (4, 35) and detachment (5) as well as prostacyclin synthesis (4) have all been shown to be serum dependent. LPS functionally interacts with numerous serum constituents; it activates the alternative complement pathway, and the intrinsic clotting and kallikrein-kinin systems (36) , and directly binds to Hageman factor (36) , high and low density lipoproteins (37), the acute phase protein, LPB (6, 10) , and sCD14 (18) . We have now demonstrated serum factors necessary for LPS-induced endothelial barrier dysfunction.
In our bovine EC system, either rabbit or human LBP alone, in the absence of other serum constituents, promoted the serum-dependent LPS-induced changes in endothelial barrier function. A dose-response relationship between the LBP concentration and this LPS effect was demonstrated. The optimal LPS/LBP ratio was 1:1. In addition, anti-human LBP antibody completely blocked the LPS-induced effect in the presence of HS. These data strongly suggest that LBP can function as an accessory molecule for LPS presentation to the EC surface. LBP is present in normal rabbit serum in concentrations of < 0.5 ,ug/ml, increasing -100-fold 24 h after induction of an acute phase response (6, 10) . In humans, LBP rises from 7.2±4.0 ,g/ml in the sera of normal subjects to 220±100 tg/ml in acute phase sera ( 38 ) . The concentration of LBP employed in our studies ( 1.2 1Ag/ml) was well within the expected concentration range found in serum of either species (6, 7) . That rabbit and human LBP as well as HS could each present LPS to bovine EC should not be surprising, as the molecule is highly conserved across species (7). Rabbit and human LBP share 69% amino acid identity and 78% nucleotide identity. An EC surface receptor that LPS-LBP complexes recognize is not known. To our knowledge, CD 14, a differentiation antigen on monocytic cells ( 14, 15, 39) , has not been demonstrated on EC. Wright et al. (12) Similarly, they did not confirm their depletion of LBP from serum. Thus, it might be possible to reconcile the observed differences in behavior of LBP in these three systems, but the explanations are not very satisfying, and the reconciliation of these differences are under investigation. sCD14 also functioned dose-dependently as an accessory molecule for the LPS-induced EC response in the absence of serum or LBP. Anti-human CD14 antibody totally blocked the LPS-induced effect in the presence of HS, but had no effect in a reconstituted serum-free LPS-LBP system. In other experiments, HS depleted of sCD 14 by immunoaffinity chromatography also failed to support the LPS effect. Thus, the CD14 that contributes to the LPS-EC interaction in our system seems to be present in a soluble or circulating form and not on the EC surface. On the basis of a semiquantitative ELISA, normal human plasma contains sCD14 at -6 ,gg/ml (16) . It has now been shown that Haemophilus influenzae LPS induces bovine pulmonary artery and brain EC cytotoxicity in the presence of HS that can be blocked by a murine monoclonal anti-CD14 antibody (3C 10); no experiments were performed in a serumfree system (32) . More recently, sCD14 has been shown to participate in LPS-induced expression ofendothelial leukocyte adhesion molecule-I by HUVEC, as well as cytotoxicity of bovine pulmonary artery ( 17) and brain microvascular (32, 35) EC. Another study has demonstrated that sCD14 is involved in the induction by LPS ofHUVEC IL-6 and IL-8 biosynthesis, as well as intercellular adhesion molecule-I and vascular-cell adhesion molecule-I expression ( 18 ) . At present, no specific bind-700 ing site on EC for LPS-sCD14 complexes is known. Human monocytes express CD 14 on their surface, and their adherence to cytokine-stimulated EC can be blocked by anti-CD 14 antibody ( 13). Whether this finding represents an EC receptor for CD 14 expressed on the monocyte surface is unknown.
We found that LBP and sCD 14, two structurally unrelated molecules, could each singularly promote LPS-induced changes in endothelial barrier function in the absence of serum. Each molecule influenced the LPS effect in a dose-dependent manner. Their contributions to the LPS effect were kinetically distinct; LBP had a much more rapid onset ofaction than did sCD 14 (1 vs 6 h). However, in the presence of serum, antibodies to either LBP or sCD 14 completely blocked the LPS effect. These results cannot be explained by cross-reactivity of the antibodies, because antibody to either LBP or sCD 14 did not cross-react with the other antigen in a serum-free reconstituted system. Further, immunodepletion ofsCD 14 did not significantly diminish serum LBP concentrations, and this sCD 14-depleted serum that contained suprathreshold concentrations of LBP failed to support the LPS effect. Thus, our data suggest that in a serum-free, reconstituted system, LBP and sCD 14 can each independently function as accessory molecules for LPS presentation, whereas in the presence of serum, both molecules are required. Perhaps an additional serum component(s) exists that participates in LPS, LBP, and sCD14 interactions. In serum, other sinks for LPS exist. For example, serum lipoproteins avidly bind up and detoxify LPS (37, 40) . For the EC to compete effectively with these other fates for LPS in serum, a more effective presentation mechanism than either LBP or sCD 14 alone may be required. In the reconstituted system, LBP and sCD 14 together enhance LPS-induced increments in transendothelial '4C-BSA flux more than either protein does alone. Whether LBP and sCD 14 function additively or synergistically is unclear. The optimal molar ratios of LBP, sCD 14, and LPS required to exert a specific biological response in a specific target tissue have not yet been defined. Alternatively, LPS complexed with both LBP and sCD 14 might operate through a third pathway. Our data are compatible with one or more finite receptor populations that recognize LPS in the presence of an accessory molecule(s). Whether these accessory molecules complex to and alter the tertiary structure ofthe LPS ligand to promote its accommodation by such an EC receptor(s) and/or directly serve as docking proteins within the EC receptor-ligand interaction itself is unknown. Whatever the mechanism(s), this ability of LBP and sCD14 to support the LPS effect cannot be ascribed to a nonspecific protein-LPS interaction; BSA, DAF, CRP, and folate-binding protein each failed to function as an accessory molecule for LPS presentation to the EC.
Humans have evolved over many thousands of years with bacteria and their endotoxins. That cells of monocyte/macrophage lineage can provide a molecule that together with an hepatocyte-derived protein can facilitate LPS-EC interaction demonstrates remarkable host adaptability to a potentially lethal substance found in both gut flora and in the external environment. Through their facilitation of the LPS-EC interaction, these accessory molecules may be central to tissue-specific responses to LPS. sCD 14 may be synthesized and shed in situ within monocyte/macrophage-containing sites where hepatocyte-synthesized LBP is excluded. The ability of these accessory molecules to pass through physiological barriers into a given body compartment, the rapidity of their appearance, and their local concentrations all may modulate LPS-induced biological responses at the ubiquitous endothelial surface. LBP facilitates LPS priming of neutrophils (40) , and sCD 14 participates in LPS-stimulated astrocytoma cell secretion ofIL-6 (17) and colonic adenocarcinoma cell secretion of IL-8 (18 
